Introduction
Graft-versus-myeloma reactivity of donor lymphocyte infusion (DLI) for relapsed multiple myeloma (MM) after allogeneic SCT is well established. Response rates of 30-50% in relapsed MM patients have been reported. 1, 2 DLI can be given as treatment for clinical relapse or as preemptive therapy after T-cell-depleted allogeneic SCT. 3 In our center, all 24 patients transplanted upfront for MM in the period from December 1997 to April 2002 intended to receive pre-emptive DLI (pDLI) after discontinuation of immunosuppression and in the absence of GVHD. We analyzed response rates and toxicity in this cohort.
Patients and methods

Patients and treatment
Twenty-four patients were treated with an allogeneic SCT for MM between December 1997 and April 2002 at the Radboud University Nijmegen Medical Centre, The Netherlands. All patients had MM stage II or III. All patients younger than 60 years and with an HLA-identical sibling were offered an allogeneic SCT, according to the HOVON 24 study. Eight patients were actually included in the HOVON 24 study, which is published, although only the Nijmegen patients received pDLI. 4 Induction therapy included 2 to 6 VAD (vincristine, adriamycin and dexamethasone) courses. Four patients received an additional course of CY (used for stem cell collection in the HOVON 24 protocol) and 16 patients were treated with intermediate-dose melphalan (two times 70 mg/m 2 ) before the transplantation. One patient received standard-dose melphalan-prednisone. Patient characteristics are shown in Table 1 . At the time this study was performed, the prognostic factors such as b-2 microglobulin and cytogenetics were not routinely tested. In 14 of the 24 patients, conventional cytogenetic analysis of bone marrow was performed before SCT: two patients had multiple structural and numerical abnormalities and one patient showed loss of chromosome 22. The conditioning regimen consisted of CY (total dose 120 mg/kg) and TBI (9 Gy) in 23 patients, and in 5 cases conditioning was intensified by the addition of idarubicin (total dose 42 mg/m 2 ). One patient with an unrelated donor received CY (120 mg/kg), TBI (9 Gy) and anti-thymocyte globulin (thymoglobulin, 8 mg/kg). Another patient was conditioned with CY (120 mg/kg) and BU (16 mg/kg) orally. The grafts were partially depleted of T cells by counterflow centrifugation as described before. 5 The grafts for two patients were prepared by CD2 and CD19 depletion (Isolex, Nexell-Baxter, Irvine, CA, USA Infusion of donor lymphocytes pDLI was given on an intention-to-treat basis and was withheld in cases of preceding GVHD4grade I, active chronic GVHD (cGVHD) and in patients who were still on immunosuppressive therapy. DLI was performed as described before. 6 Briefly, lymphocytes were obtained from the original stem cell donor by leukapheresis using the blood cell separator Baxter CS 3000 (Baxter, Deerfield, IL, USA) or the Fresenius AS 104 (Fresenius, Oberursel, Germany). Lymphocytes were administered to the patient within 3 h of completion of the leukapheresis procedure. No GVHD prophylaxis was administered after the infusion of the donor lymphocytes. The first nine patients received 0.1 Â 10 8 CD3 þ cells/kg, but because of GVHD, the dose of lymphocytes was reduced to 0.05 Â 10 8 CD3 þ cells/kg in the next four patients. Therapeutic DLI (tDLI) was given for progression or relapse of MM and T-cell dose varied from 0.05 Â 10 8 to 0.7 Â 10 8 CD3 þ cells/kg.
Response criteria
Complete remission (CR) was defined as complete disappearance of M-protein from blood and/or urine by immunofixation and normalization of the bone marrow. 7 Partial remission (PR) was defined as a decrease of more than 50% of the M-protein in the peripheral blood and a decrease in urinary light-chain excretion of more than 90% or to less than 0.2 g/24 h. Minimal response (MR) was defined as 25% or more decrease of monoclonal proteins in the peripheral blood and/or more than 50% decrease in urinary light-chain excretion. Molecular remission was defined as a negative patient-specific PCR. The sensitivity of the PCR is 1 Â 10
À5
.
End points and statistical analysis
The data were analyzed in April 2006. End points included response rate, overall survival (OS) and progression-free survival (PFS). PFS was determined from transplantation until progression, relapse or death, whichever came first. OS was calculated from transplantation until death. PFS and OS were estimated by the Kaplan-Meier method.
Multivariate analysis was performed using the Wilks' l-test.
Results
Outcome and toxicity of SCT Twenty of 24 patients (83%) were in remission before transplantation, including 4 patients in CR and 16 in PR. Three patients showed a minimal response and one was refractory to the chemotherapy before transplantation. Twenty-two patients were evaluable 3-6 months after transplantation. Two patients had died at this time, one from infection and one from progressive disease. The overall response rate (of all 24 patients) after allogeneic SCT was 83% (20 of 24 patients) with 10 patients (42%) in CR and 10 in PR.
Acute GVHD (aGVHD) occurred in 12 patients (50%): seven patients (29%) with grade I, three patients (13%) with GVHD grade II and two patients (8%) with grade III. Twenty-three patients were evaluable for cGVHD. Seven patients (30%) developed cGVHD, which was limited in five patients and extensive in two patients.
DLI after SCT
Thirteen of the 24 patients (54%) received pDLI after SCT. Median time from SCT to pDLI was 7.5 months (range, 3.5-13.3 months). Six patients (46%) developed GVHD after pDLI: grade I in two patients, grade II and III in one patient each and grade IV GVHD in two patients. Eleven of 24 patients did not receive pDLI, because of GVHD (n ¼ 5), rejection (n ¼ 1), rapid progressive disease (n ¼ 1), death (n ¼ 1), poor performance status (n ¼ 1) and donorrelated problems (n ¼ 2). Four patients received tDLI for progressive disease, without previously having had pDLI. Median time to tDLI was 18.7 months (range, 13.6-47.2 months). Two patients developed GVHD after tDLI, and this was grade I and IV in each patient.
Outcome of DLI and OS Disease status at the time of pDLI was CR in five patients, VGPR in one, PR in four, one patient was nonsecreting and two patients were not in remission (Table 2) . Overall, 10 patients reached a clinical CR after pDLI. Five patients were in CR before pDLI and the five patients with (VG)PR after SCT also reached a clinical CR after pDLI. Three patients relapsed later; two patients are alive and still receiving treatment for MM.
Nine out of 13 patients (69%) who received pDLI are alive at present and seven are in CCR. In four of the patients in CCR, a patient-specific PCR for the immunoglobulin heavy-chain rearrangement was generated and all four patients are persistently PCR-negative. 8 In two patients, the PCR was negative before pDLI, and in one patient, the PCR was weakly positive and became negative after pDLI. In another patient, the PCR was not tested between SCT and pDLI. Overall, of the seven patients in CCR, three were in clinical CR before pDLI. Four patients in CCR reached CR only after pDLI.
Four of the 13 patients who were given pDLI died: both patients who were not in remission after SCT died, one from progressive disease and other from GVHD, respectively. The third patient responded to DLI, which was confirmed by a negative patient-specific PCR, but died of relapsed MM 3.5 years after pDLI. Finally, the patient who was nonsecreting died of progressive disease. In all patients reaching CCR, the M-protein was o10 g/l after SCT, indicating that tumor load at the time of DLI is related to the final outcome. Multivariate analysis was performed to study whether b-2 microglobulin, M-protein level or percentage of plasma cells was correlated with CCR. None of these factors correlated significantly with CCR, but patient numbers are too small to draw definite conclusions.
Of the four patients who received tDLI, one patient died owing to GHVD, another achieved a CR, but relapsed and died from progressive disease. Two patients entered a partial response and are alive at 64 and 58 months after SCT, respectively. Figures 1 and 2 show the OS and disease-free survival. Eleven out of 24 patients (46%) are alive at present, with a median follow-up of 67 months (range, 48-100 months) from SCT. Seven of these patients are in CCR; four patients relapsed or showed progressive disease. Thirteen patients died: seven patients (29%) owing to transplantrelated mortality (TRM) within 1 year after SCT and five patients (20%) owing to progressive disease. One patient Table 2 Disease status after SCT, response after DLI and at last follow-up in 13 patients treated with pDLI Pre-emptive DLI in multiple myeloma H Levenga et al died 18 months after SCT from GVHD after tDLI for progression of MM.
Discussion
Since partial T-cell depletion of the graft is associated with a higher risk of relapse, a cohort of 24 patients (transplanted from 1997 to 2001) was planned for pDLI to boost graftversus-tumor reactivity. Since only 13 patients received pDLI, our results have to be interpreted with caution. Nevertheless, in our cohort, 7 of 24 patients (29%) are in CCR with a median follow-up of 67 months and all 7 had received pDLI. Eight of the 24 patients were also included in the Dutch HOVON 24 trial, and described before. 4 However, pDLI was not given in the other centers participating in this study. In the HOVON 24 trial, only 3 of 53 patients (6%) were in CCR with a median follow-up of 20 months. This suggests that immunotherapy after T-cell-depleted SCT enhances the graftversus-myeloma reactivity. In four patients with a clinical CCR, plasma cells were cryopreserved at diagnosis to set up a patient-specific IgH PCR and all four patients were in molecular remission. A recent study showed that molecular remission after SCT predicts a better relapse-free survival, although relapses after many years can occur. 9 There is a strong association between graft-versusmyeloma reactivity and GVHD. The strongest predictors for response to DLI (therapeutic) in relapsed MM patients are the occurrence of aGVHD and cGVHD after DLI. 1, 10 In reduced-intensity SCT, patients with cGVHD have a significantly longer median event-free survival than patients without cGVHD. 11 In one multicentered study, patients with cGVHD had a more than two times less probability of relapse. 12 It is striking that in our study, no CCRs were reached among patients with GVHD after SCT and those who did not receive pDLI for this reason. The mechanism behind this observation is unknown; however, we made a similar observation in other hematological malignancies. 3 The most serious toxicity of DLI is GVHD. Because two patients developed aGVHD grade IV after pDLI, the preemptive T-cell dose was decreased from 0.1 Â 10 8 CD3 þ cells/kg to 0.05 Â 10 8 CD3 þ cells/kg. Four patients received the low-dose pDLI, and none of these patients developed GVHD of severity more than grade I. A comparable strategy is to start with low-dose DLI, followed by dose escalation if the patient does not reach CR. Peggs et al. 13 studied the application of dose-escalated DLI following reduced-intensity SCT in patients with lymphoid malignancies. However, separation of graft-versus-malignancy from GVHD was achieved in only a minority of the patients. Another approach to reduce the incidence of GVHD after DLI is the transfer of CD8-depleted donor lymphocytes. In a recent study by Meyer et al., 14 11 patients with high-risk hematological malignancies received a total of 21 CD8-depleted pDLIs. Two patients with HLA-C mismatched donors developed grade II and III aGVHD followed by limited cGVHD. These prophylactic CD8-depleted DLIs accelerate immune reconstitution; however, the effect on disease relapse rate has to be studied. Combination therapy of low-dose thalidomide and DLI for MM is described by Kroger et al. 15 In this study, patients with progressive or residual disease after allogeneic SCT receive low-dose DLI (0.05 Â 10 8 CD3 þ cells/kg for patients with related donors) in combination with low-dose thalidomide. Two patients developed aGVHD grade I of the skin and also two patients developed de novo cGVHD.
Only 54% of the patients were able to receive pDLI. This is comparable with the study of Alyea et al. 16 In their study of T-cell-depleted (CD6-depleted) allogeneic SCT followed by CD4 þ DLI, 58% of the patients actually received DLI. The other patients did not receive DLI because of SCTrelated complications or early relapse. In our study, patients actually receiving pDLI are those who had no complications from the SCT or rapidly progressive disease. Since pDLI was given relatively late (at a median of 7.5 months after SCT) the conclusion on the favorable effect of pDLI is skewed towards good prognosis patients. However, analyses of PFS and OS were made on intention-to-treat basis.
Despite the favorable outcome in patients receiving pDLI, TRM was high (29%). TRM in allogeneic SCT for MM prepared with myeloablative conditioning varies from 17 to 38%. 17, 18 Nonmyeloablative SCT significantly reduced TRM, even in patients with advanced age and comorbidity. 19 However, in the setting of nonmyeloablative SCT with unmanipulated grafts, the incidence of cGVHD is high. The optimal procedure of performing allogeneic SCT in MM is still unknown.
An important question remains the place of upfront allogeneic SCT in patients with newly diagnosed MM, and which patients may benefit the most. Results of a prospective multicentered trial comparing tandem autologous SCT and tandem autologous-allogeneic SCT were published recently. 20 Patients with newly diagnosed MM and with two adverse prognostic factors were included. After four courses of VAD, these patients received highdose melphalan followed by autologous SCT. Then, depending on the availability of an HLA-identical sibling, these patients received either an RIC-allogeneic SCT or a second autologous SCT. There was no significant difference in EFS and OS between these two strategies. On the other hand, a recent prospective study of Bruno et al. 21 showed a superior outcome for the tandem autologous-allogeneic approach compared with tandem autologous transplant.
On the basis of the data in our study and the reduction in TRM after reduced conditioning, we are performing a pilot study in which patients receive an autologous SCT followed within 6 months by a partially T-cell-depleted allogeneic SCT after reduced-intensity conditioning with fludarabine (120 mg/m 2 ) and CY (4800 mg/m 2 ). From January 2006, 13 patients were transplanted according to this regimen and all 13 patients engrafted. Currently, these patients receive low-dose DLI after discontinuation of immunosuppressive therapy. Low-dose DLI, with escalation, is given to patients not in CR (measured with PCR in the absence of M-protein) and in the absence of GVHD.
Further studies are needed for better immunomodulatory therapies after partially T-cell-depleted allogeneic SCT for patients with MM. With reduced-intensity conditioning regimens, the TRM after allogeneic SCT is significantly reduced; however, effectively boosting graft-versus-myeloma reactivity without GVHD as side effect remains a dilemma in allogeneic SCT for MM.
